Hematologic Malignancies: A Review of Key Clinical Studies
  • CME

May 29-31, 2020; Online at meetings.asco.org/am
Expert faculty review and share their insights and perspectives on key findings in hematologic malignancies presented at the virtual 2020 ASCO Annual Meeting.
Ian W. Flinn, MD, PhD
Shaji Kumar, MD
Farhad Ravandi, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: September 23, 2020 Expiration: September 22, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with hematologic malignancies
  • Identify subpopulations of patients with hematologic malignancies most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with hematologic malignancies
  • Consider how new trial findings might affect treatment of hematologic malignancies clinical practice in the future

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Shaji Kumar, MD

Department of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Amgen, Bristol-Myers Squibb, CARsgen, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Takeda, and Tenebio; consulting fees (paid to his institution) from AbbVie, Amgen, Celgene, Genentech, Janssen, Molecular Partners, and Takeda; and personal payment from Cellectar, GeneCentrix, and Oncopeptides.
Farhad Ravandi, MD

Professor of Medicine
Chief,
Section of Developmental Therapeutics
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, MacroGenics, Orsenix, and Xencor and consulting fees from AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Jazz, Novartis, Orsenix, and Xencor.
Ian W. Flinn, MD, PhD

Director, Lymphoma Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees from Curis, Forma, Forty Seven, Genentech, Gilead Sciences, Incyte, Infinity, Janssen, Juno, Karyopharm Therapeutics, Kite, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Roches, Takeda, Teva, TG Therapeutics, Trillium, Unum, and Verastem and has personal ownership in Johnson & Johnson.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer reports that his spouse has ownership interest in AstraZeneca.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with hematologic malignancies.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with hematologic malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 23, 2020, through September 22, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Download this short summary slideset of key topics in the evolving use of BCMA-targeted agents for RR multiple myeloma from Clinical Care Options.

Natalie S. Callander, MD Released: October 23, 2020

Clinical commentary by Dr. William Wierda on personalizing frontline treatment for chronic lymphocytic leukemia (CLL) from Clinical Care Options (CCO)

William G. Wierda, MD, PhD Released: October 22, 2020

Downloadable resource from CCO on the diagnosis and management of mycosis fungoides

Prof Julia Scarisbrick Released: October 21, 2020

Download this slideset to review the latest clinical data informing optimal management strategies for follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue